Financial Snapshot

Revenue
$925.0K
TTM
Gross Margin
Net Earnings
-$41.98M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
909.16%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$137.4M
Q3 2024
Cash
Q3 2024
P/E
-7.793
Dec 02, 2024 EST
Free Cash Flow
-$83.69M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $25.00M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $25.00M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $11.19M $17.97M $21.54M $17.21M $18.13M $15.84M $14.85M $9.260M $5.540M $4.300M $1.780M $1.640M $1.730M
YoY Change -37.73% -16.57% 25.14% -5.07% 14.46% 6.67% 60.37% 67.15% 28.84% 141.57% 8.54% -5.2%
% of Gross Profit
Research & Development $44.39M $41.13M $39.16M $24.34M $4.417M $41.79M $36.27M $28.38M $15.80M $18.08M $7.599M $6.045M $8.580M
YoY Change 7.94% 5.02% 60.87% 451.14% -89.43% 15.23% 27.78% 79.64% -12.61% 137.91% 25.7% -29.54%
% of Gross Profit
Depreciation & Amortization $3.300M $1.561M $1.306M $785.0K $340.0K $289.0K $360.0K $135.9K $59.57K $130.8K $130.0K
YoY Change 111.4% 19.53% 66.37% 130.88% 17.65% -19.72% 128.21% -54.45% 0.6%
% of Gross Profit
Operating Expenses $55.58M $59.10M $39.16M $24.34M $70.96M $57.62M $51.12M $37.65M $21.34M $22.38M $9.376M $7.681M $10.43M
YoY Change -5.95% 50.9% 60.87% -65.69% 23.14% 12.73% 35.79% 76.41% -4.63% 138.64% 22.07% -26.36%
Operating Profit -$55.58M -$59.10M -$60.70M -$33.73M -$70.96M -$32.62M -$51.12M -$37.65M
YoY Change -5.95% -2.64% 79.96% -52.47% 117.51% -36.18% 35.79%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense $12.00K $1.582M $18.00K $500.0K $1.000K $4.000K $4.000K $1.000K -$420.0K $451.0K $42.92K $9.470K -$190.0K
YoY Change -99.24% 8688.89% -96.4% 49900.0% -75.0% 0.0% 300.0% -100.24% -193.13% 950.72% 353.25% -104.98%
% of Operating Profit
Other Income/Expense, Net -$28.00K -$42.00K $6.000K $451.0K $1.517M $1.039M $936.0K $643.0K -$520.0K -$1.652M $642.0K $9.114K -$50.00K
YoY Change -33.33% -800.0% -98.67% -70.27% 46.01% 11.0% 45.57% -223.65% -68.52% -357.32% 6944.11% -118.23%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income -$36.32M -$57.58M -$60.69M -$33.28M -$67.31M -$9.108M -$6.425M -$5.265M -$21.86M -$24.03M -$8.734M -$7.672M -$10.66M
YoY Change -36.93% -5.13% 82.38% -50.56% 639.05% 41.76% 22.03% -75.91% -9.02% 175.1% 13.84% -28.03%
Income Tax $2.300M $0.00 $0.00 $0.00 -$5.000K $42.29K -$150.0K
% Of Pretax Income
Net Earnings -$36.30M -$57.56M -$60.69M -$33.28M -$69.44M -$31.59M -$50.18M -$37.00M -$21.86M -$24.03M -$8.729M -$7.714M -$10.51M
YoY Change -36.93% -5.17% 82.38% -52.08% 119.86% -37.06% 35.62% 69.27% -9.02% 175.25% 13.15% -26.6%
Net Earnings / Revenue -126.34%
Basic Earnings Per Share -$1.04 -$1.10 -$0.64
Diluted Earnings Per Share -$2.83 -$1.04 -$1.10 -$0.64 -$2.569M -$1.343M -$2.140M -$1.959M -$1.729M -$2.772M -$29.10M -$807.3K -$1.101M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $197.2M $96.38M $142.5M $192.6M $143.1M $76.90M $108.1M $103.1M $74.50M $39.10M $13.80M $2.000M $9.200M
YoY Change 104.55% -32.35% -26.03% 34.59% 86.09% -28.86% 4.85% 38.39% 90.54% 183.33% 590.0% -78.26%
Cash & Equivalents $148.2M $37.89M $142.5M $192.6M $143.1M $51.90M $39.40M $28.60M $37.40M $6.600M $3.700M $700.0K $700.0K
Short-Term Investments $48.95M $58.50M $0.00 $56.10M $70.80M $35.00M $24.20M $2.800M $0.00
Other Short-Term Assets $3.191M $2.750M $1.522M $1.100M $300.0K $100.0K $1.500M $0.00 $0.00
YoY Change 16.04% 80.68% 38.36% 200.0% -93.33%
Inventory
Prepaid Expenses
Receivables $900.0K $500.0K $200.0K $700.0K $400.0K $0.00 $100.0K $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $200.0K
Total Short-Term Assets $200.3M $99.13M $144.0M $194.5M $143.6M $77.20M $108.8M $103.5M $74.80M $39.30M $15.30M $2.100M $9.500M
YoY Change 102.1% -31.15% -25.97% 35.45% 86.01% -29.04% 5.12% 38.37% 90.33% 156.86% 628.57% -77.89%
Property, Plant & Equipment $20.95M $15.88M $17.22M $13.70M $2.800M $400.0K $900.0K $800.0K $100.0K $100.0K $100.0K $200.0K $300.0K
YoY Change 31.96% -7.78% 25.68% 389.29% 600.0% -55.56% 12.5% 700.0% 0.0% 0.0% -50.0% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $50.00M $38.50M $2.000M $0.00
YoY Change -100.0% 29.87% 1825.0%
Other Assets $1.272M $936.0K $1.928M $1.900M $0.00 $100.0K $600.0K $0.00 $0.00 $300.0K $0.00 $0.00
YoY Change 35.9% -51.45% 1.47% -100.0% -83.33% -100.0%
Total Long-Term Assets $22.23M $16.81M $19.27M $16.00M $3.400M $400.0K $1.500M $50.90M $38.50M $2.100M $300.0K $200.0K $400.0K
YoY Change 32.18% -12.76% 20.46% 370.59% 750.0% -73.33% -97.05% 32.21% 1733.33% 600.0% 50.0% -50.0%
Total Assets $222.6M $115.9M $163.3M $210.5M $147.0M $77.60M $110.3M $154.4M $113.3M $41.40M $15.60M $2.300M $9.900M
YoY Change
Accounts Payable $2.596M $478.0K $526.0K $1.300M $1.600M $700.0K $6.000M $6.900M $2.200M $700.0K $600.0K $200.0K $300.0K
YoY Change 443.1% -9.13% -59.54% -18.75% 128.57% -88.33% -13.04% 213.64% 214.29% 16.67% 200.0% -33.33%
Accrued Expenses $20.05M $10.44M $8.055M $6.500M $3.100M $3.900M $4.900M $2.700M $2.600M $4.500M $1.800M $200.0K $300.0K
YoY Change 92.01% 29.66% 23.92% 109.68% -20.51% -20.41% 81.48% 3.85% -42.22% 150.0% 800.0% -33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $42.00K $140.0K $55.00K $0.00 $100.0K $300.0K $0.00
YoY Change -70.0% 154.55% -100.0%
Total Short-Term Liabilities $22.97M $11.06M $8.636M $7.900M $4.700M $4.600M $11.00M $9.500M $4.800M $5.200M $2.600M $400.0K $600.0K
YoY Change 107.67% 28.09% 9.32% 68.09% 2.17% -58.18% 15.79% 97.92% -7.69% 100.0% 550.0% -33.33%
Long-Term Debt $65.00K $233.0K $67.00K $100.0K $100.0K $0.00 $0.00 $0.00 $0.00 $0.00 $2.000M $0.00 $0.00
YoY Change -72.1% 247.76% -33.0% 0.0% -100.0%
Other Long-Term Liabilities $13.51M $10.32M $11.70M $11.30M $400.0K $300.0K $500.0K $200.0K $100.0K $100.0K $2.800M $1.100M $700.0K
YoY Change 30.9% -11.75% 3.5% 2725.0% 33.33% -40.0% 150.0% 100.0% 0.0% -96.43% 154.55% 57.14%
Total Long-Term Liabilities $13.58M $10.56M $11.76M $11.40M $500.0K $300.0K $500.0K $200.0K $100.0K $100.0K $4.800M $1.100M $700.0K
YoY Change 28.62% -10.27% 3.18% 2180.0% 66.67% -40.0% 150.0% 100.0% 0.0% -97.92% 336.36% 57.14%
Total Liabilities $36.55M $21.62M $20.40M $19.30M $5.300M $4.900M $11.40M $9.700M $4.900M $5.300M $7.500M $1.500M $1.300M
YoY Change 69.08% 5.97% 5.69% 264.15% 8.16% -57.02% 17.53% 97.96% -7.55% -29.33% 400.0% 15.38%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 55.22M shares 55.04M shares 51.83M shares
Diluted Shares Outstanding 55.22M shares 55.04M shares 51.83M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $327.1 Million

About Neurogene Inc.

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.

Industry: Pharmaceutical Preparations Peers: ABVC BIOPHARMA, INC. Ainos, Inc. Aravive, Inc. Oruka Therapeutics, Inc. Avalo Therapeutics, Inc. Codiak BioSciences, Inc. Comera Life Sciences Holdings, Inc. Marker Therapeutics, Inc. MAIA Biotechnology, Inc.